Login to Your Account

Cyclical Response

Cancer and Autoimmune Top Therapeutic Areas for Deals

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, April 22, 2013

According to data from Deloitte Recap LLC, cancer drugs are the most popular compounds to partner, making up 33 percent of all deals in 2012. The popularity has increased from the five years prior to that when oncology drugs made up 24 percent of the licensing deals. In the first quarter of 2013, the fraction held steady at one third of all deals.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription